BTK inhibitors

Pharma

Novartis expands Rhapsido's growing reach in chronic hives

After a first approval in chronic hives, Novartis’ Rhapsido is expanding its reach with a new FDA nod that comes with a notable ‘first’ for the field.

Fraiser Kansteiner Oct 7, 2026 2:27pm

Eli Lillys booth at ASH 2025 prominently featuring Jaypirca

Lilly’s BTK drug Jaypirca enters first-line CLL

Oct 2, 2026 4:15pm

Novartis' BTK drug clears ph. 3 in MS sans liver safety signal

Sep 1, 2026 11:10am

BeOne’s Brukinsa hits goal in lymphoma confirmatory trial

Jun 30, 2026 6:00am

Lilly oncology chief ‘blown away’ by new Jaypirca CLL data

Jun 15, 2026 8:25am

Lilly touts Jaypirca fixed-duration win in ‘ambitious’ CLL trial

Apr 13, 2026 10:16am